10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          To compare the performance of the PRECISE scoring system against several MRI-derived delta-radiomics models for predicting histopathological prostate cancer (PCa) progression in patients on active surveillance (AS).

          Methods

          The study included AS patients with biopsy-proven PCa with a minimum follow-up of 2 years and at least one repeat targeted biopsy. Histopathological progression was defined as grade group progression from diagnostic biopsy. The control group included patients with both radiologically and histopathologically stable disease. PRECISE scores were applied prospectively by four uro-radiologists with 5–16 years’ experience. T2WI- and ADC-derived delta-radiomics features were computed using baseline and latest available MRI scans, with the predictive modelling performed using the parenclitic networks (PN), least absolute shrinkage and selection operator (LASSO) logistic regression, and random forests (RF) algorithms. Standard measures of discrimination and areas under the ROC curve (AUCs) were calculated, with AUCs compared using DeLong’s test.

          Results

          The study included 64 patients (27 progressors and 37 non-progressors) with a median follow-up of 46 months. PRECISE scores had the highest specificity (94.7%) and positive predictive value (90.9%), whilst RF had the highest sensitivity (92.6%) and negative predictive value (92.6%) for predicting disease progression. The AUC for PRECISE (84.4%) was non-significantly higher than AUCs of 81.5%, 78.0%, and 80.9% for PN, LASSO regression, and RF, respectively ( p = 0.64, 0.43, and 0.57, respectively). No significant differences were observed between AUCs of the three delta-radiomics models (p-value range 0.34–0.77).

          Conclusions

          PRECISE and delta-radiomics models achieved comparably good performance for predicting PCa progression in AS patients.

          Key Points

          The observed high specificity and PPV of PRECISE are complemented by the high sensitivity and NPV of delta-radiomics, suggesting a possible synergy between the two image assessment approaches.

          The comparable performance of delta-radiomics to PRECISE scores applied by expert readers highlights the prospective use of the former as an objective and standardisable quantitative tool for MRI-guided AS follow-up.

          • The marginally superior performance of parenclitic networks compared to conventional machine learning algorithms warrants its further use in radiomics research.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s00330-021-08151-x.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Regression Shrinkage and Selection Via the Lasso

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach

                Bookmark

                Author and article information

                Contributors
                ns784@medschl.cam.ac.uk
                Journal
                Eur Radiol
                Eur Radiol
                European Radiology
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0938-7994
                1432-1084
                13 July 2021
                13 July 2021
                2022
                : 32
                : 1
                : 680-689
                Affiliations
                [1 ]GRID grid.5335.0, ISNI 0000000121885934, Department of Radiology, , Addenbrooke’s Hospital and University of Cambridge, ; Cambridge, UK
                [2 ]GRID grid.5335.0, ISNI 0000000121885934, Department of Radiology, , University of Cambridge School of Clinical Medicine, ; Box 218, Cambridge Biomedical Campus, Cambridge, CB2 0QQ UK
                [3 ]GRID grid.5335.0, ISNI 0000000121885934, Cancer Research UK Cambridge Centre, , University of Cambridge, ; Cambridge, UK
                [4 ]GRID grid.5846.f, ISNI 0000 0001 2161 9644, School of Physics, Engineering & Computer Science, , University of Hertfordshire, ; Hatfield, UK
                [5 ]GRID grid.448878.f, ISNI 0000 0001 2288 8774, Department of Paediatrics and Paediatric Infectious Diseases, , Sechenov First Moscow State Medical University, ; Moscow, Russia
                [6 ]GRID grid.28171.3d, ISNI 0000 0001 0344 908X, Department of Applied Mathematics, , Lobachevsky State University of Nizhny Novgorod, ; Nizhny Novgorod, Russia
                [7 ]GRID grid.83440.3b, ISNI 0000000121901201, Department of Mathematics and Institute for Women’s Health, , University College London, ; London, UK
                [8 ]GRID grid.448878.f, ISNI 0000 0001 2288 8774, World-Class Research Center “Digital Biodesign and Personalised Healthcare”, , Sechenov First Moscow State Medical University, ; Moscow, Russia
                [9 ]GRID grid.5335.0, ISNI 0000000121885934, Division of Urology, Department of Surgery, , University of Cambridge, ; Cambridge, UK
                [10 ]GRID grid.5335.0, ISNI 0000000121885934, Cambridge Urology Translational Research and Clinical Trials Office, , University of Cambridge, ; Cambridge, UK
                Author information
                http://orcid.org/0000-0003-4500-9714
                Article
                8151
                10.1007/s00330-021-08151-x
                8660717
                34255161
                a68a321c-6535-499e-b5fc-66555b7c1c49
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 30 March 2021
                : 27 May 2021
                : 13 June 2021
                Funding
                Funded by: National Institute of Health Research Cambridge Biomedical Research Centre
                Funded by: Cancer Research UK
                Award ID: C197/A16465
                Funded by: Engineering and Physical Sciences Research Council Imaging Centre in Cambridge and Manchester
                Funded by: Cambridge Experimental Cancer Medicine Centre
                Funded by: Medical Research Council
                Award ID: MR/R02524X/1
                Award Recipient :
                Funded by: Ministry of Science and Higher Education of the Russian Federation
                Award ID: 075-15-2020-926
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100005370, Gates Cambridge Trust;
                Categories
                Urogenital
                Custom metadata
                © The Author(s), under exclusive licence to European Society of Radiology 2022

                Radiology & Imaging
                prostate cancer,magnetic resonance imaging,active surveillance,precise,machine learning

                Comments

                Comment on this article